This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
coronavirus disease | 99 |
acute respiratory | 90 |
novel coronavirus | 74 |
respiratory syndrome | 72 |
clinical characteristics | 60 |
intensive care | 54 |
severe acute | 50 |
syndrome coronavirus | 44 |
eur respir | 43 |
risk factors | 43 |
doc id | 43 |
cord uid | 43 |
respiratory distress | 40 |
clinical features | 39 |
air pollution | 38 |
critically ill | 36 |
cohort study | 34 |
newborn babies | 34 |
distress syndrome | 33 |
severe covid | 32 |
care unit | 30 |
respiratory failure | 30 |
ill patients | 29 |
hospitalized patients | 29 |
middle east | 28 |
mechanical ventilation | 28 |
east respiratory | 28 |
patients infected | 27 |
prognostic models | 26 |
chest ct | 26 |
hospital admission | 25 |
clinical course | 24 |
cancer patients | 23 |
clinical outcomes | 23 |
health care | 23 |
nasal cannula | 22 |
central hospital | 22 |
clinical trials | 22 |
systematic review | 21 |
copd patients | 21 |
oxygen saturation | 20 |
among patients | 20 |
affiliated hospital | 19 |
computed tomography | 19 |
net benefit | 19 |
pulmonary aspergillosis | 18 |
increased risk | 17 |
may also | 17 |
national health | 17 |
clinical deterioration | 17 |
flow nasal | 16 |
lung cancer | 16 |
epithelial cells | 16 |
retrospective cohort | 16 |
carbon monoxide | 15 |
least one | 15 |
chronic obstructive | 15 |
obstructive pulmonary | 15 |
clinical practice | 15 |
respiratory tract | 15 |
pulmonary disease | 15 |
world health | 14 |
case series | 14 |
confirmed cases | 14 |
converting enzyme | 14 |
factors associated | 14 |
pulmonary function | 14 |
composite endpoints | 14 |
cov infection | 13 |
china clinical | 13 |
health commission | 13 |
health organization | 13 |
ct scans | 13 |
severe illness | 13 |
severe cases | 13 |
invasive ventilation | 13 |
previous studies | 12 |
pulmonary embolism | 12 |
chest imaging | 12 |
medical university | 12 |
infected patients | 12 |
nucleic acid | 12 |
disease severity | 12 |
study clinical | 12 |
lung injury | 12 |
patients admitted | 12 |
sample size | 12 |
univariable predictors | 12 |
high risk | 11 |
noninvasive ventilation | 11 |
respiratory compliance | 11 |
health service | 11 |
coronavirus pneumonia | 11 |
infectious disease | 11 |
critical care | 11 |
confirmed covid | 11 |
first affiliated | 11 |
infected pneumonia | 10 |
upper respiratory | 10 |
available data | 10 |
united states | 10 |
respiratory support | 10 |
dispersion distance | 10 |
asthmatic patients | 10 |
healthcare workers | 10 |
icu patients | 10 |
machine learning | 10 |
severe disease | 10 |
public health | 10 |
hospitalised patients | 10 |
room air | 10 |
swab robot | 10 |
clinical trial | 10 |
hubei province | 10 |
severe pneumonia | 10 |
present study | 10 |
mortality rate | 10 |
chest radiographs | 10 |
airway pressure | 10 |
respiratory rate | 10 |
prototype ventilator | 10 |
patients received | 10 |
median age | 10 |
positive airway | 10 |
observational study | 10 |
ct scan | 10 |
alveolar volume | 9 |
clinical data | 9 |
smoking status | 9 |
risk factor | 9 |
confidence interval | 9 |
thrombotic risk | 9 |
patients without | 9 |
randomised controlled | 9 |
lower respiratory | 9 |
care workers | 9 |
continuous positive | 9 |
invasive pulmonary | 9 |
infectious diseases | 9 |
lymphocyte ratio | 9 |
retrospective study | 9 |
tested positive | 9 |
nccid will | 8 |
ct findings | 8 |
described previously | 8 |
pao fio | 8 |
descriptive study | 8 |
respiratory infections | 8 |
bench test | 8 |
test datasets | 8 |
associated pulmonary | 8 |
prospective cohort | 8 |
respiratory diseases | 8 |
medical device | 8 |
external validation | 8 |
traditional chinese | 8 |
social distancing | 8 |
adult inpatients | 8 |
early warning | 8 |
nationwide analysis | 8 |
diffusion capacity | 8 |
baseline characteristics | 8 |
acute pulmonary | 8 |
lung function | 8 |
tb burden | 8 |
patients receiving | 8 |
hospital stay | 7 |
pharyngeal swab | 7 |
adjuvant chemotherapy | 7 |
venturi mask | 7 |
clinical management | 7 |
thoracic imaging | 7 |
one comorbidity | 7 |
many patients | 7 |
diagnostic yield | 7 |
swab specimens | 7 |
thoracic society | 7 |
may help | 7 |
wuhan clinical | 7 |
asthma exacerbation | 7 |
cystic fibrosis | 7 |
body temperature | 7 |
care units | 7 |
source hardware | 7 |
last accessed | 7 |
patients hospitalized | 7 |
chinese medicine | 7 |
observational cohort | 7 |
pressure support | 7 |
two patients | 7 |
critical illness | 7 |
tract swabs | 7 |
adult patients | 7 |
hospital mortality | 7 |
regression model | 7 |
warning score | 7 |
viral infections | 7 |
positive patients | 7 |
receiver operating | 7 |
date last | 7 |
limit time | 7 |
oxygen therapy | 7 |
glass opacity | 7 |
controlled trials | 7 |
supplementary table | 7 |
nasopharyngeal swabs | 7 |
prognostic model | 7 |
right lung | 7 |
univariable predictor | 7 |
negative swabs | 7 |
feature selection | 7 |
reactive protein | 7 |
thrombotic events | 7 |
risk assessment | 7 |
negative upper | 7 |
candidate model | 7 |
coronary heart | 7 |
serum gm | 7 |
study population | 7 |
candidate prognostic | 7 |
multicenter study | 7 |
operating characteristic | 7 |
igg igm | 7 |
preliminary report | 7 |
standard deviation | 6 |
poor clinical | 6 |
lung disease | 6 |
ventilated patients | 6 |
intrauterine transmission | 6 |
regression models | 6 |
altitude pulmonary | 6 |
cov replication | 6 |
three patients | 6 |
decision curve | 6 |
time horizons | 6 |
systemic corticosteroids | 6 |
informed consent | 6 |
bioaerosols generated | 6 |
patients treated | 6 |
polymerase chain | 6 |
lactate dehydrogenase | 6 |
fio ratio | 6 |
european respiratory | 6 |
hospitalised covid | 6 |
laboratory results | 6 |
acute lung | 6 |
individual patients | 6 |
treatment strategies | 6 |
low risk | 6 |
lung compliance | 6 |
tb cases | 6 |
chain reaction | 6 |
discriminating univariable | 6 |
tb deaths | 6 |
coronavirus infections | 6 |
future studies | 6 |
small airway | 6 |
health services | 6 |
acquired pneumonia | 6 |
coronavirus infection | 6 |
mechanical ventilators | 6 |
chronic respiratory | 6 |
imported cases | 6 |
prediction model | 6 |
alveolar epithelial | 6 |
diffusing capacity | 6 |
open source | 6 |
mortality among | 6 |
different phenotypes | 6 |
viral infection | 6 |
radiological characteristics | 6 |
patient population | 6 |
breathing discomfort | 6 |
interquartile range | 6 |
sore throat | 6 |
venous thromboembolism | 6 |
active tuberculosis | 6 |
patients may | 6 |
lombardy region | 6 |
retrospective case | 6 |
new york | 6 |
pcr covid | 6 |
first study | 6 |
clinical manifestations | 6 |
original intended | 6 |
mechanically ventilated | 6 |
hospital staff | 6 |
current smoking | 6 |
cardiovascular diseases | 6 |
endothelial cells | 6 |
british society | 6 |
candidate models | 6 |
radiological suspicion | 6 |
imaging data | 6 |
recovery trial | 6 |
social contacts | 6 |
monoxide uptake | 6 |
critical cases | 6 |
online supplement | 6 |
northern italy | 6 |
limited fov | 6 |
aerosol dispersion | 6 |
total number | 6 |
lesion range | 6 |
median time | 5 |
heart disease | 5 |
prediction models | 5 |
significant difference | 5 |
ace expression | 5 |
emergency department | 5 |
one study | 5 |
model performance | 5 |
endothelial cell | 5 |
living systematic | 5 |
china epidemiological | 5 |
study showed | 5 |
cftr modulators | 5 |
disease courses | 5 |
recent reports | 5 |
calculated using | 5 |
logistic regression | 5 |
faulty triggering | 5 |
medical college | 5 |
patient management | 5 |
two groups | 5 |
healthcare systems | 5 |
thrombotic complications | 5 |
ct imaging | 5 |
hazards ratio | 5 |
two cases | 5 |
angiotensin ii | 5 |
interim guidance | 5 |
age groups | 5 |
among hospitalised | 5 |
adverse outcome | 5 |
generating procedures | 5 |
medical treatment | 5 |
consecutive patients | 5 |
transmission potential | 5 |
ng ml | 5 |
invasive mechanical | 5 |
better understand | 5 |
model based | 5 |
laboratory findings | 5 |
commercially available | 5 |
glass opacities | 5 |
reduced mers | 5 |
iga responses | 5 |
clinical presentation | 5 |
ill adults | 5 |
mean age | 5 |
inflammatory response | 5 |
time horizon | 5 |
years old | 5 |
potential risk | 5 |
ct features | 5 |
index model | 5 |
composite endpoint | 5 |
coronavirus sars | 5 |
one case | 5 |
commercial device | 5 |
bal gm | 5 |
inflammatory cytokines | 5 |
best model | 5 |
human lung | 5 |
severe hypoxaemia | 5 |
bilevel pressure | 5 |
flow oxygen | 5 |
day mortality | 5 |
pneumonia caused | 5 |
neonatal infections | 5 |
multivariable prediction | 5 |
severe patients | 5 |
ventilatory support | 5 |
clinical outcome | 5 |
inhaled corticosteroids | 5 |
one patient | 5 |
fungal co | 5 |
rheumatoid arthritis | 5 |
potential impact | 5 |
risk score | 5 |
treated cells | 5 |
experienced progression | 5 |
immune response | 5 |
suspected covid | 5 |
controlled trial | 5 |
saudi arabia | 5 |
mortality rates | 5 |
ct value | 5 |
initially igg | 5 |
general population | 5 |
nasopharyngeal swab | 5 |
income countries | 5 |
organ systems | 5 |
moderate cases | 5 |
cytokine storm | 5 |
hospitalized covid | 5 |
dedicated respiratory | 5 |
patient age | 5 |
severity risk | 5 |
janus kinase | 5 |
significantly lower | 5 |
characteristic curve | 5 |
york city | 5 |
icu intensive | 5 |
admission oxygen | 5 |
curve analysis | 5 |
respiratory viruses | 5 |
test results | 5 |
routine clinical | 5 |
nrs outside | 5 |
invasive aspergillosis | 5 |
expiratory pressures | 5 |
corticosteroid use | 5 |
underwent bronchoscopy | 5 |
median follow | 5 |
palliative chemotherapy | 5 |
icu admission | 5 |
primary outcome | 5 |
different respiratory | 5 |
organ failure | 5 |
blood pressure | 5 |
respiratory disease | 5 |
acid detection | 5 |
human coronavirus | 5 |
term outcomes | 5 |
recently published | 5 |
viral endocytosis | 4 |
csa treatment | 4 |
pneumonia associated | 4 |
pneumonia severity | 4 |
disease progression | 4 |
tissue factor | 4 |
concordantly negative | 4 |
disease clinical | 4 |
line chemotherapy | 4 |
cigarette use | 4 |
posterior pharyngeal | 4 |
delivery systems | 4 |
prospective study | 4 |
older patients | 4 |
bronchoalveolar lavage | 4 |
patients using | 4 |
cell lung | 4 |
patients outside | 4 |
respiratory monitoring | 4 |
high mortality | 4 |
mass index | 4 |
study date | 4 |
airborne precautions | 4 |
significantly reduced | 4 |
smoking prevalence | 4 |
pulmonary vascular | 4 |
became igg | 4 |
extracellular traps | 4 |
influenza infection | 4 |
ers ats | 4 |
creative commons | 4 |
compassionate use | 4 |
adverse events | 4 |
first cohort | 4 |
energy ct | 4 |
risk stratification | 4 |
severe complications | 4 |
second affiliated | 4 |
airway epithelia | 4 |
nine hospitals | 4 |
widely used | 4 |
medical devices | 4 |
viral titers | 4 |
pulmonary rehabilitation | 4 |
care admission | 4 |
high doses | 4 |
may improve | 4 |
pressure waveform | 4 |
done using | 4 |
multiple organ | 4 |
relatively low | 4 |
venous thromboembolic | 4 |
success rate | 4 |
adaptive trial | 4 |
severe coronavirus | 4 |
clinical utility | 4 |
attribution non | 4 |
may increase | 4 |
learning model | 4 |
acute hypoxemic | 4 |
body mass | 4 |
hfnc flow | 4 |
cox proportional | 4 |
required intensive | 4 |
every weeks | 4 |
cell entry | 4 |
ards subphenotypes | 4 |
inspiratory pressures | 4 |
asthma exacerbations | 4 |
data collection | 4 |
consensus statement | 4 |
personal protective | 4 |
jaki may | 4 |
chest radiographic | 4 |
nasal oxygen | 4 |
missing data | 4 |
negative nasopharyngeal | 4 |
commons attribution | 4 |
clinical research | 4 |
arterial oxygen | 4 |
practice guidelines | 4 |
swab quality | 4 |
alveolar capillary | 4 |
vertical transmission | 4 |
psi scoring | 4 |
authors declare | 4 |
typical acute | 4 |
tidal volumes | 4 |
blood vessels | 4 |
performed using | 4 |
results suggest | 4 |
innate immune | 4 |
adverse outcomes | 4 |
active tb | 4 |
cyclophilin inhibitors | 4 |
commercial ventilator | 4 |
fov group | 4 |
incubation period | 4 |
new zealand | 4 |
icu resources | 4 |
detection rate | 4 |
increased susceptibility | 4 |
nasal mask | 4 |
clinical observations | 4 |
transparent reporting | 4 |
south africa | 4 |
case fatality | 4 |
multiple imputation | 4 |
worse outcomes | 4 |
min oxygen | 4 |
inflammatory effects | 4 |
dni order | 4 |
oxygen inhalation | 4 |
older age | 4 |
cox regression | 4 |
prognostic performance | 4 |
breathing pattern | 4 |
first covid | 4 |
gas exchange | 4 |
tb diagnosis | 4 |
common comorbidities | 4 |
impaired diffusion | 4 |
organ dysfunction | 4 |
national early | 4 |
cumulative incidence | 4 |
commercial licence | 4 |
health concern | 4 |
artificial intelligence | 4 |
patients presented | 4 |
infection control | 4 |
disease outcomes | 4 |
protective equipment | 4 |
exclude covid | 4 |
staff contamination | 4 |
ct values | 4 |
ground glass | 4 |
three newborn | 4 |
airway epithelial | 4 |
lopinavir ritonavir | 4 |
mild cases | 4 |
preventive strategies | 4 |
fatality rates | 4 |
pandemic influenza | 4 |
cov infections | 4 |
oxygen supplementation | 4 |
electronic health | 4 |
obstructive restrictive | 4 |
hypoxemic respiratory | 4 |
np swabs | 4 |
wide range | 4 |
clinical decision | 4 |
social isolation | 4 |
relatively short | 4 |
clinical use | 4 |
loaded breathing | 4 |
common abnormality | 4 |
virus transmission | 4 |
healthy volunteers | 4 |
submitted work | 4 |
soft palate | 4 |
pharyngeal wall | 4 |
cardiovascular comorbidities | 4 |
pulmonary oedema | 4 |
study design | 4 |
generated shorter | 4 |
arterial blood | 4 |
range score | 4 |
global health | 4 |
lung tissue | 4 |
respiratory infection | 4 |
improve outcomes | 4 |
associated acute | 4 |
intended outcome | 4 |
proportional hazards | 4 |
control measures | 4 |
aerosol generating | 4 |
selected patients | 4 |
bronchial epithelial | 4 |
pulmonary angiography | 4 |
consider delaying | 4 |
pcr test | 4 |
blood gas | 4 |
mg kg | 4 |
poorer clinical | 4 |
clinically relevant | 4 |
patients across | 4 |
will help | 4 |
five test | 4 |
respiratory journal | 4 |
consider giving | 4 |
patients recovered | 4 |
electronic nicotine | 4 |
neutrophil extracellular | 4 |
threshold probabilities | 4 |
alveolar damage | 4 |
may lead | 4 |
swab sampling | 4 |
licence key | 3 |
small airways | 3 |
severe group | 3 |
erj ref | 3 |
oxygen administration | 3 |
adverse reactions | 3 |
developing severe | 3 |
weight heparin | 3 |
possible benefits | 3 |
hospital deterioration | 3 |
patient ratio | 3 |
capillary leak | 3 |
turned moderate | 3 |
population size | 3 |
copd chronic | 3 |
interventions necessary | 3 |
american thoracic | 3 |
cases accounted | 3 |
ethics committee | 3 |
protein kinase | 3 |
main causes | 3 |
direct comparison | 3 |
scoring systems | 3 |
dear editor | 3 |
sars coronavirus | 3 |
contact rates | 3 |
respiratory system | 3 |
kinase inhibitors | 3 |
noninvasive respiratory | 3 |
oropharyngeal swabs | 3 |
asymptomatic infection | 3 |
many studies | 3 |
required hospitalisation | 3 |
continuous variables | 3 |
previously confirmed | 3 |
negative patients | 3 |
assisted ventilation | 3 |
support ventilator | 3 |
healthy individuals | 3 |
time frame | 3 |
performance characteristics | 3 |
five days | 3 |
short term | 3 |
staff involved | 3 |
current pandemic | 3 |
methods results | 3 |
written informed | 3 |
clinical risk | 3 |
study protocol | 3 |
different severities | 3 |
outbreak dynamics | 3 |
chronic health | 3 |
establish risk | 3 |
prior covid | 3 |
existing literature | 3 |
mortality risk | 3 |
study covid | 3 |
spike protein | 3 |
patients according | 3 |
preliminary screening | 3 |
us study | 3 |
seattle region | 3 |
current study | 3 |
familial cluster | 3 |
bench study | 3 |
wide spectrum | 3 |
suspected infection | 3 |
virus infection | 3 |
family cluster | 3 |
global burden | 3 |
region covid | 3 |
institutional review | 3 |
covid patients | 3 |
also lead | 3 |
hazards regression | 3 |
county hospital | 3 |
data access | 3 |
sampling force | 3 |
serious adverse | 3 |
service availability | 3 |
diseases hospital | 3 |
final diagnosis | 3 |
critical icu | 3 |
ct scanners | 3 |
pollution research | 3 |
unwell patients | 3 |
within hours | 3 |
imaging features | 3 |
time reverse | 3 |
alternative diagnosis | 3 |
contracting covid | 3 |
statistical significance | 3 |
potential harm | 3 |
two cohorts | 3 |
important role | 3 |
hong kong | 3 |
suggestive ct | 3 |
british thoracic | 3 |
respiratory unit | 3 |
auroc area | 3 |
never smokers | 3 |
symptom onset | 3 |
host factors | 3 |
relatively small | 3 |
validation dataset | 3 |
air changes | 3 |
receptor type | 3 |
recent study | 3 |
high flow | 3 |
pulmonary compliance | 3 |
nicotine delivery | 3 |
identify patients | 3 |
well known | 3 |
stage patients | 3 |
large proportion | 3 |
pulmonary thrombosis | 3 |
decreased alveolar | 3 |
per minute | 3 |
disease course | 3 |
false negative | 3 |
signaling pathways | 3 |
roc curve | 3 |
annals swabs | 3 |
clinical implementation | 3 |
gas flow | 3 |
decision support | 3 |
outside wuhan | 3 |
expert panel | 3 |
oral cs | 3 |
international concern | 3 |
evenly distributed | 3 |
disease patients | 3 |
suspected cases | 3 |
throughput sequencing | 3 |
human bronchial | 3 |
smoke dispersion | 3 |
sepsis campaign | 3 |
chest wall | 3 |
pulmonary fibrosis | 3 |
care systems | 3 |
data analysis | 3 |
infection may | 3 |
disease onset | 3 |
high peep | 3 |
related genes | 3 |
either individual | 3 |
randomized controlled | 3 |
patients present | 3 |
health status | 3 |
tb health | 3 |
partial pressure | 3 |
chained equations | 3 |
clinical phenotypes | 3 |
higher risk | 3 |
clinical complications | 3 |
interferon regulatory | 3 |
march th | 3 |
regression analyses | 3 |
ct images | 3 |
patients remain | 3 |
disease epidemiology | 3 |
data capture | 3 |
patients showed | 3 |
eleven patients | 3 |
ct semantic | 3 |
viral rna | 3 |
previous negative | 3 |
lung epithelial | 3 |
much less | 3 |
health evaluation | 3 |
retrospective analysis | 3 |
diffuse alveolar | 3 |
hospitalized cases | 3 |
united kingdom | 3 |
abnormal pulmonary | 3 |
first time | 3 |
chest radiography | 3 |
categorical variables | 3 |
march st | 3 |
control study | 3 |
may vary | 3 |
positive end | 3 |
pulmonary emboli | 3 |
retrospective review | 3 |
reverse transcriptase | 3 |
combination model | 3 |
cell foci | 3 |
global tuberculosis | 3 |
models evaluated | 3 |
using bootstrapping | 3 |
ventilator prototype | 3 |
included models | 3 |
important limitations | 3 |
individual patient | 3 |
may cause | 3 |
build non | 3 |
rare diseases | 3 |
direct evidence | 3 |
radiographic assessment | 3 |
trial visits | 3 |
intrauterine vertical | 3 |
clinic visits | 3 |
service disruption | 3 |
free replication | 3 |
good enough | 3 |
pooled prevalence | 3 |
rare disease | 3 |
respiratory covid | 3 |
cancer care | 3 |
nonbreather mask | 3 |
developed countries | 3 |
oxygen flow | 3 |
single comorbidity | 3 |
month follow | 3 |
male gender | 3 |
op swab | 3 |
like illness | 3 |
airway epithelium | 3 |
clinical application | 3 |
sleep apnea | 3 |
reproduction number | 3 |
small cohort | 3 |
every day | 3 |
statistical analyses | 3 |
age distribution | 3 |
significant comorbidity | 3 |
hospital clinical | 3 |
less likely | 3 |
discharged patients | 3 |
pathological findings | 3 |
external population | 3 |
case study | 3 |
hypercapnic acute | 3 |
disease duration | 3 |
xiangyang central | 3 |
using machine | 3 |
physical distancing | 3 |
asthmatic controls | 3 |
primary human | 3 |
viral respiratory | 3 |
epidemiological characteristics | 3 |
benefit ratio | 3 |
increased thrombotic | 3 |
sick patients | 3 |
patient stratification | 3 |
ffp masks | 3 |
tomography imaging | 3 |
pandemic date | 3 |
randomised clinical | 3 |
commonly used | 3 |
semantic features | 3 |
patients died | 3 |
preliminary analysis | 3 |
intelligent oropharyngeal | 3 |
jak inhibitors | 3 |
normal breathing | 3 |
longer disease | 3 |
chinese cities | 3 |
population density | 3 |
greater net | 3 |
cytotoxic chemotherapy | 3 |
hospitalized asthmatics | 3 |
infection prevention | 3 |
receiving nrs | 3 |
humoral immune | 3 |
study found | 3 |
breathing difficulty | 3 |
positive sars | 3 |
normally distributed | 3 |
two newborn | 3 |
improves outcome | 3 |
may explain | 3 |
population smoking | 3 |
higher levels | 3 |
main outcomes | 3 |
total flow | 3 |
patients experienced | 3 |
ppiase activity | 3 |
disease date | 3 |
five cohorts | 3 |
different ages | 3 |
function test | 3 |
indicating person | 3 |
immunocompromised patients | 3 |
individual prognosis | 3 |
breaths min | 3 |
tracheal aspirate | 3 |
obstructive atelectasis | 3 |
antiviral activity | 3 |
determined based | 3 |
early experience | 3 |
recovered covid | 3 |
medical technology | 3 |
health records | 3 |
respiratory treatments | 3 |
tertiary hospitals | 3 |
diagnostic accuracy | 3 |
among hospitalized | 3 |
aerosol particle | 3 |
recently reported | 3 |
best performing | 3 |
scientific evidence | 3 |
previous study | 3 |
several limitations | 3 |
early stage | 3 |
also found | 3 |
premature phenotyping | 3 |
cisplatin etoposide | 3 |
risk associated | 3 |
statistically significant | 3 |
covid pandemic | 3 |
lung edema | 3 |
patients included | 3 |
scientific community | 3 |
odds ratio | 3 |
human alveolar | 3 |
kidney injury | 3 |
places needed | 3 |
significant differences | 3 |
model discrimination | 3 |
characterisation protocol | 3 |
liver function | 3 |
erroneous treatment | 3 |
imaging database | 3 |
potentially useful | 3 |
unclear whether | 3 |
reference hospital | 3 |
develop severe | 3 |
hospital discharge | 3 |
will include | 3 |
disease control | 3 |
host factor | 3 |
type natriuretic | 3 |
cesarean section | 3 |
normal compliance | 3 |
risk groups | 3 |
microvascular thrombosis | 3 |
corona virus | 3 |
cell infection | 3 |
pressure devices | 3 |
control group | 3 |
collected data | 3 |
platelet count | 3 |
three different | 3 |
average range | 3 |
berlin definition | 3 |
breathing frequencies | 3 |
exact test | 3 |
conventional nasal | 3 |
critically unwell | 3 |
profound hypoxaemia | 3 |
coronavirus indicating | 3 |
person transmission | 3 |
membrane oxygenation | 3 |
joint mission | 3 |
three negative | 3 |
included patients | 3 |
increased production | 3 |
aspergillus antigen | 3 |
personal fees | 3 |
using hfno | 3 |
pulmonary edema | 3 |
different levels | 3 |
calibration parameters | 3 |
way anova | 3 |
hypoxic vasoconstriction | 3 |
surviving sepsis | 3 |
higher proportion | 3 |
elderly patients | 3 |
patients required | 3 |
viral clearance | 3 |
deceased patients | 3 |
intended endpoint | 3 |
dose reduction | 3 |
clinical characterisation | 3 |
peripheral blood | 3 |
clinical information | 3 |
diabetes mellitus | 3 |
viral pneumonia | 3 |
thromboembolic events | 3 |
taking ics | 3 |
oxygen supply | 3 |
patient simulator | 3 |
low dose | 3 |
clinical care | 3 |
potential benefit | 3 |
left lung | 3 |
requiring hospital | 3 |
positive result | 3 |
ct pulmonary | 3 |
respiratory symptoms | 3 |
secretory iga | 3 |
reduced alveolar | 3 |
model linear | 3 |
cov propagation | 3 |
national covid | 3 |
care system | 3 |
specimen collection | 3 |
acute physiology | 3 |
great interest | 3 |
clinical symptoms | 3 |
among covid | 3 |
ternary complex | 3 |
competing interests | 3 |
extra care | 3 |
limited settings | 3 |
prognostic scores | 3 |
deep learning | 3 |
including patients | 3 |
computer algorithms | 3 |
ex novo | 3 |
patients requiring | 3 |
retrospective studies | 3 |
gene expression | 3 |
function tests | 3 |
critical appraisal | 3 |
confounding factors | 3 |
elderly covid | 3 |
medical image | 3 |
fatality rate | 3 |
general hospital | 3 |
ci confidence | 3 |
current smokers | 3 |
high proportion | 3 |
airway resistance | 3 |
limited number | 3 |
developed specifically | 3 |
ards acute | 3 |
study group | 3 |
respiratory mechanics | 3 |
gina step | 3 |
image analysis | 3 |
expiratory pressure | 3 |
may result | 3 |
two studies | 3 |
without cancer | 3 |
disease pneumonia | 3 |
severe influenza | 3 |
deaths occurring | 3 |
still lacking | 3 |
requiring admission | 3 |
myocardial infarction | 3 |
hidden link | 3 |
cigarette vapour | 3 |
autonomous regions | 3 |
medical records | 3 |
age range | 3 |
lung volume | 3 |
myocardial injury | 3 |
endothelial injury | 3 |
less severe | 3 |
positive results | 3 |
risk prediction | 3 |
altitude disease | 3 |
bal culture | 3 |
less common | 3 |
serum iga | 3 |
personalised approach | 3 |
data indicate | 3 |
severely ill | 3 |
studies describing | 3 |
either deterioration | 3 |
nccid data | 3 |
new coronavirus | 3 |
severity index | 3 |
european countries | 3 |
significantly increased | 3 |
hardware description | 3 |
pregnant women | 3 |
data points | 3 |
bal sampling | 3 |
china joint | 3 |
close contact | 3 |
healthy subjects | 3 |
modelling approaches | 3 |
spike glycoprotein | 2 |
high oxygen | 2 |
strongest predictor | 2 |
burn devices | 2 |
cholinergic system | 2 |
impeding cellular | 2 |
respiratory wards | 2 |
tidal volume | 2 |
study using | 2 |
haemorrhagic alveolar | 2 |
six patients | 2 |
combined covid | 2 |
models truly | 2 |
restrictive loads | 2 |
five hospitals | 2 |
currently unknown | 2 |
natriuretic peptide | 2 |
take body | 2 |
health systems | 2 |
specific models | 2 |
internal validation | 2 |
vaping may | 2 |
considered three | 2 |
model minus | 2 |
hpn ovgo | 2 |
major comorbidities | 2 |
outbreak associated | 2 |
via upregulation | 2 |
plasminogen activator | 2 |
requiring oxygen | 2 |
severe sepsis | 2 |
classic ards | 2 |
pulmonary blood | 2 |
imaging research | 2 |
hospital departments | 2 |
predicting mortality | 2 |
metrics derived | 2 |
helmet cpap | 2 |
reaction assay | 2 |
signaling events | 2 |
endoscopic procedures | 2 |
proportional hazard | 2 |
median body | 2 |
mrna levels | 2 |
physicians worldwide | 2 |
pandemic testing | 2 |
pneumonia tended | 2 |
university paris | 2 |
intensive unit | 2 |
open holes | 2 |
respiratory ward | 2 |
may suffer | 2 |
discovery populations | 2 |
one may | 2 |
management strategy | 2 |
high plasma | 2 |
systemic iga | 2 |
four times | 2 |
distance decreased | 2 |
ventilation may | 2 |
discomfort scoring | 2 |
fibrosis patients | 2 |
prone position | 2 |
five patients | 2 |
putting aside | 2 |
treatment subgroups | 2 |
growth rate | 2 |
tb outcomes | 2 |
using niv | 2 |
previous reports | 2 |
singapore clinical | 2 |
exhaled air | 2 |
tobacco survey | 2 |
airway inflammation | 2 |
oral administration | 2 |
early prediction | 2 |
college london | 2 |
ii receptor | 2 |
tb incidence | 2 |
induced iga | 2 |
may well | 2 |
side effects | 2 |
tb lesions | 2 |
predominantly spread | 2 |
coronavirus outbreak | 2 |
capillary pressure | 2 |
sb kgu | 2 |
american association | 2 |
data extraction | 2 |
data used | 2 |
ardsnet protocol | 2 |
babies days | 2 |
terminal kinase | 2 |
separate cohorts | 2 |
area prevalence | 2 |
pemetrexed maintenance | 2 |
ii score | 2 |
using noninvasive | 2 |
acute high | 2 |
withdrawal controversy | 2 |
intended leak | 2 |
china acute | 2 |
disease outbreak | 2 |
current guidelines | 2 |
system inhibitors | 2 |
low proportion | 2 |
help identify | 2 |
demonstrated consistently | 2 |
confer damaging | 2 |
case detection | 2 |
death among | 2 |
dose oral | 2 |
old woman | 2 |
distributed learning | 2 |
aspergillosis complicating | 2 |
creatine kinase | 2 |
quantitative ct | 2 |
showed greater | 2 |
support strategies | 2 |
ct scanning | 2 |
comprehensive searching | 2 |
reasonable discrimination | 2 |
poorer prognosis | 2 |
excluding patients | 2 |
coronavirus cases | 2 |
clinical findings | 2 |
corticosteroid therapy | 2 |
expert consensus | 2 |
mild pneumonia | 2 |
january st | 2 |
infected calu | 2 |
two different | 2 |
low pressures | 2 |
animal experiments | 2 |
data will | 2 |
data show | 2 |
corporeal membrane | 2 |
authors observed | 2 |
sdstnm i | 2 |
different types | 2 |
global interest | 2 |
greater disease | 2 |
palliative setting | 2 |
voluntary subjects | 2 |
prophylactic use | 2 |
study period | 2 |
model included | 2 |
multinational registry | 2 |
antimicrobial prescribing | 2 |
emerging infection | 2 |
rapid spread | 2 |
mothers right | 2 |
province autonomous | 2 |
models developed | 2 |
patients compared | 2 |
validation study | 2 |
severe human | 2 |
alvar agusti | 2 |
influenza virus | 2 |
near normal | 2 |
reduced cell | 2 |
effective treatments | 2 |
respiratory imaging | 2 |
low respiratory | 2 |
also showed | 2 |
require hospitalisation | 2 |
pulmonary embolisms | 2 |
cov titers | 2 |
may still | 2 |
th may | 2 |
study area | 2 |
studies mentioned | 2 |
high affinity | 2 |
human airway | 2 |
vary among | 2 |
patients hospitalised | 2 |
csa induced | 2 |
recent years | 2 |
findings suggest | 2 |
scientific rigor | 2 |
following data | 2 |
burden countries | 2 |
respiratory care | 2 |
ai models | 2 |
sometimes beyond | 2 |
emerging infectious | 2 |
short half | 2 |
strongly suggest | 2 |
single center | 2 |
cpap niv | 2 |
wider problem | 2 |
individual phenotypes | 2 |
go fast | 2 |
acute pe | 2 |
urgent life | 2 |
paper published | 2 |
actual meaning | 2 |
study aimed | 2 |
smoke used | 2 |
training dataset | 2 |
infectious particle | 2 |
proinflammatory cytokine | 2 |
temporal trend | 2 |
enforced reallocation | 2 |
evaluated performance | 2 |
data collected | 2 |
altitude areas | 2 |
life saving | 2 |
severe critical | 2 |
clinics reported | 2 |
patients already | 2 |
shenzhen hospital | 2 |
remote monitoring | 2 |
clot thickens | 2 |
study risk | 2 |
endocrine comorbidities | 2 |
current validation | 2 |
years vs | 2 |
ohso hl | 2 |
personal protection | 2 |
vascular injury | 2 |
woman treated | 2 |
feasibility study | 2 |
clinical dynamics | 2 |
human serum | 2 |
median arterial | 2 |
important issues | 2 |
omalizumab therapy | 2 |
systems across | 2 |
model intercept | 2 |
toronto area | 2 |
therapeutic interventions | 2 |
probability scores | 2 |
reported previously | 2 |
cell lines | 2 |
patients reached | 2 |
blood lymphocytes | 2 |
requiring invasive | 2 |
class i | 2 |
scientific debate | 2 |
per deciliter | 2 |
research teams | 2 |
proper fit | 2 |
ventilator provided | 2 |
district hospital | 2 |
rarely encountered | 2 |
outbreak size | 2 |
recommend vigilance | 2 |
confirmed case | 2 |
patient may | 2 |
cost device | 2 |
offering diagnostic | 2 |
chest tightness | 2 |
reasonable scientific | 2 |
clinical microbiology | 2 |
age may | 2 |
clinical phenotyping | 2 |
limited data | 2 |
conductance regulator | 2 |
trial sites | 2 |
imbalanced learning | 2 |
disruption effects | 2 |
inform clinical | 2 |
arterial partial | 2 |
standard deviations | 2 |
patient falls | 2 |
outbreak response | 2 |
technical information | 2 |
sample sizes | 2 |
pivotal regulator | 2 |
patients remained | 2 |
respiratory load | 2 |
medical resources | 2 |
variable pharmacodynamics | 2 |
vpap st | 2 |
access committee | 2 |
far enough | 2 |
cytokines simultaneously | 2 |
prevent use | 2 |
severely affected | 2 |
will collect | 2 |
research letter | 2 |
mainly confined | 2 |
replacing intravenous | 2 |
single centre | 2 |
exhaled smoke | 2 |
earlier stage | 2 |
next pandemic | 2 |
plateau phase | 2 |
information may | 2 |
written consent | 2 |
dimer levels | 2 |
via different | 2 |
early stages | 2 |
agent responsible | 2 |
prospective monocentric | 2 |
strategies https | 2 |
unknown whether | 2 |
good fov | 2 |
nrs modes | 2 |
outcome measures | 2 |
therapeutic options | 2 |
novel illness | 2 |
asthma controller | 2 |
related mortality | 2 |
carry exhaled | 2 |
yei ifs | 2 |
draw attention | 2 |
may exert | 2 |
might confer | 2 |
including ground | 2 |
equally important | 2 |
trials evaluating | 2 |
cannula size | 2 |
outcome probability | 2 |
hypoxic pulmonary | 2 |
publicly available | 2 |
tract infections | 2 |
nitric oxide | 2 |
th covid | 2 |
isolation crucial | 2 |
heavier clinical | 2 |
transmission occurs | 2 |
markedly restricts | 2 |
care management | 2 |
illness among | 2 |
considered statistically | 2 |
italian reference | 2 |
closely monitored | 2 |
admission data | 2 |
will acquire | 2 |
interstitial thickening | 2 |
potentially increased | 2 |
test conditions | 2 |
particle release | 2 |
features similar | 2 |
help clinicians | 2 |
bitter waters | 2 |
learning approaches | 2 |
cohort studies | 2 |
vulnerable population | 2 |
higher pressures | 2 |
nachr antagonists | 2 |
hxte gc | 2 |
predictor variables | 2 |
cost bilevel | 2 |
provincial municipalities | 2 |
electronic medical | 2 |
saving therapy | 2 |
several clinical | 2 |
influenza increasing | 2 |
future crises | 2 |
total gas | 2 |
therapeutic option | 2 |
without chronic | 2 |
paykel healthcare | 2 |
expert opinion | 2 |
invasive ventilator | 2 |
well liberate | 2 |
exclusion criteria | 2 |
smoking rates | 2 |
medications used | 2 |
complement mediated | 2 |
positive pressure | 2 |
panel report | 2 |
high fio | 2 |
clinicians worldwide | 2 |
lower biological | 2 |
nasal pressure | 2 |
pilot study | 2 |
antiviral therapy | 2 |
slow increase | 2 |
eligibility criteria | 2 |
built using | 2 |
nrs applied | 2 |
heart diseases | 2 |
cardiac diseases | 2 |
iga production | 2 |
receptor blockers | 2 |
novel therapies | 2 |
serial measurements | 2 |
increasingly recognised | 2 |
sputum cells | 2 |
widely available | 2 |
center study | 2 |
quantitative computed | 2 |
disease covid | 2 |
small sample | 2 |
disease prognosis | 2 |
cov infected | 2 |
final model | 2 |
incomplete identification | 2 |
courses compared | 2 |
without comorbidity | 2 |
tuberculosis co | 2 |
immunological features | 2 |
care society | 2 |
viral inclusion | 2 |
days since | 2 |
autopsy findings | 2 |
perfusion scintigraphy | 2 |
monoxide diffusion | 2 |
aerosol producing | 2 |
respiratory society | 2 |
male sex | 2 |
active breathing | 2 |
aucs ranging | 2 |
diagnostic test | 2 |
pulmonary capillary | 2 |
cell differential | 2 |
still hospitalized | 2 |
required hospitalization | 2 |
overburdened critical | 2 |
rapid review | 2 |
tb disease | 2 |
big data | 2 |
longitudinal study | 2 |
best interests | 2 |
oxygen masks | 2 |
day survival | 2 |
tb treatment | 2 |
acute exacerbations | 2 |
autonomous county | 2 |
first case | 2 |
blood urea | 2 |
two categories | 2 |
assessed discrimination | 2 |
uk covid | 2 |
ct angiography | 2 |
early identification | 2 |
predictors measured | 2 |
th percentile | 2 |
clinical significance | 2 |
differential count | 2 |
false positive | 2 |
supportive care | 2 |
vitro evidence | 2 |
china medical | 2 |
sz ildnd | 2 |
widespread clinical | 2 |
imaging performed | 2 |
published studies | 2 |
pcr testing | 2 |
convenient oral | 2 |
acute kidney | 2 |
may differ | 2 |
hfno outside | 2 |
prone positioning | 2 |
icu beds | 2 |
tissue injury | 2 |
help medical | 2 |
recommended screening | 2 |
unit admission | 2 |
four patients | 2 |
cardiac troponin | 2 |
history taking | 2 |
complete blood | 2 |
findings related | 2 |
urgently needed | 2 |
temporal changes | 2 |
global adult | 2 |
using bio | 2 |
knowledge gap | 2 |
many countries | 2 |
novel prognostic | 2 |
thromboembolic disease | 2 |
hospital affiliated | 2 |
using predictors | 2 |
performance might | 2 |
epidemiologic features | 2 |
evaluation ii | 2 |
stage iv | 2 |
oral application | 2 |
cohort follow | 2 |
impaired pulmonary | 2 |
suspected concomitant | 2 |
pneumonia following | 2 |
may occur | 2 |
mipg mg | 2 |
monoclonal antibody | 2 |
pulmonary sequelae | 2 |
phase trial | 2 |
typical biologic | 2 |
electronic cigarette | 2 |
safety signals | 2 |
gm negative | 2 |
calibration slope | 2 |
labor costs | 2 |
related intensive | 2 |
vaccine development | 2 |
abnormal results | 2 |
similar extent | 2 |
whether smoke | 2 |
mitigation measures | 2 |
miracle trial | 2 |
inequalities across | 2 |
regions provincial | 2 |
describes clinical | 2 |
correspondence concerning | 2 |
failure assessment | 2 |
predict clinical | 2 |
uk patients | 2 |
two hospitals | 2 |
laboratory abnormalities | 2 |
case numbers | 2 |
often require | 2 |
proctor hoc | 2 |
bal samples | 2 |
days post | 2 |
swab samples | 2 |
simulated patients | 2 |
radiographic appearance | 2 |
extension studies | 2 |
inspiratory oxygen | 2 |
digital display | 2 |
emergency situation | 2 |
possible association | 2 |
hospitalization management | 2 |
sickle cell | 2 |
comorbid conditions | 2 |
ox hu | 2 |
tomography pulmonary | 2 |
treatment arms | 2 |
affb yln | 2 |
laboratory bench | 2 |
arduino nano | 2 |
earliest date | 2 |
patients among | 2 |
quick progression | 2 |
data regarding | 2 |
previously reported | 2 |
term omalizumab | 2 |
interests regarding | 2 |
aspergillosis invasive | 2 |
mouse model | 2 |
patients rated | 2 |
remain negative | 2 |
normal lung | 2 |
historic opportunity | 2 |
enhanced iga | 2 |
priori univariable | 2 |
resourced regions | 2 |
tube connecting | 2 |
smoke imaging | 2 |
rate might | 2 |
increasing numbers | 2 |
aabip guideline | 2 |
outcomes among | 2 |
transcriptase polymerase | 2 |
electronic cigarettes | 2 |
systems overload | 2 |
viral transmission | 2 |
halo sign | 2 |
resource allocation | 2 |
treated outside | 2 |
respiratory allergy | 2 |
cannula generated | 2 |
million people | 2 |
host inflammatory | 2 |
lung pattern | 2 |
patients nccid | 2 |
stimulating factor | 2 |
studies may | 2 |
lung abnormalities | 2 |
fatal acute | 2 |
models represents | 2 |
public places | 2 |
thoracic radiology | 2 |
multivariate cox | 2 |
weeks instead | 2 |
incubation periods | 2 |
large droplets | 2 |
functional receptor | 2 |
diagnostic algorithm | 2 |
putative invasive | 2 |
mtb rif | 2 |
truly reflect | 2 |
tobacco product | 2 |
op swabs | 2 |
virus disease | 2 |
lco may | 2 |
real time | 2 |
eight centers | 2 |
imputed datasets | 2 |
hour interval | 2 |
breathing patient | 2 |
many hospital | 2 |
care utilization | 2 |
sichuan province | 2 |
load corresponding | 2 |
available via | 2 |
inclusion bodies | 2 |
asthmatics accounted | 2 |
mortality prediction | 2 |
patient cohorts | 2 |
whether air | 2 |
classified according | 2 |
airway obstruction | 2 |
frequent blood | 2 |
influenza complications | 2 |
vast majority | 2 |
two consecutive | 2 |
damaging effects | 2 |
routinely performed | 2 |
cell count | 2 |
sampling success | 2 |
period retrospective | 2 |
inspiratory effort | 2 |
still unclear | 2 |
support covid | 2 |
convalescent plasma | 2 |
blebs rupture | 2 |
validation data | 2 |
whether social | 2 |
comprehensive peer | 2 |
inspiratory pressure | 2 |
pulmonary vasoconstriction | 2 |
exercise capacity | 2 |
i read | 2 |
flj ql | 2 |
potential association | 2 |
adaptive synthetic | 2 |
agusti succumbs | 2 |
adverse impact | 2 |
among others | 2 |
using hfnc | 2 |
ctn sites | 2 |
drug therapies | 2 |
ards patients | 2 |
systems may | 2 |
chest computed | 2 |
patients ranging | 2 |
prognostic factors | 2 |
linear predictors | 2 |
oxygen fraction | 2 |
two diseases | 2 |
airflow obstruction | 2 |
post hoc | 2 |
mediated micro | 2 |
task force | 2 |
shorter distance | 2 |
initial administration | 2 |
serious shortage | 2 |
consecutive adults | 2 |
china key | 2 |
pressure transducers | 2 |
reduced compliance | 2 |
liberation army | 2 |
pressures set | 2 |
overall rate | 2 |
dependent aurocs | 2 |
size nasal | 2 |
total lung | 2 |
invasive respiratory | 2 |
level data | 2 |
op np | 2 |
also limit | 2 |
jinyintan hospital | 2 |
responses observed | 2 |
among adults | 2 |
large nasal | 2 |
clinical judgement | 2 |
second hospital | 2 |
manual curation | 2 |
recent meta | 2 |
six month | 2 |
blood transfusions | 2 |
clinical specimens | 2 |
associated kinase | 2 |
using standard | 2 |
therapeutic potential | 2 |
offset terms | 2 |
study dutch | 2 |
prevent erroneous | 2 |
pleural pressures | 2 |
may carry | 2 |
fatal cases | 2 |
extracellular matrix | 2 |
initially thought | 2 |
outside hubei | 2 |
study prevalence | 2 |
particles dispersing | 2 |
hospitalised adults | 2 |
per hour | 2 |
mild illness | 2 |
murine mers | 2 |
participant data | 2 |
transmission outside | 2 |
county central | 2 |
severe reductions | 2 |
hypercoagulable state | 2 |
treatment scheme | 2 |
traditional imaging | 2 |
preserving distributed | 2 |
short period | 2 |
available ventilators | 2 |
progression scale | 2 |
eortc host | 2 |
mainly based | 2 |
authors also | 2 |
strong predictors | 2 |
communityacquired pneumonia | 2 |
population study | 2 |
immunosuppressive chemotherapy | 2 |
complete case | 2 |
without comprehensive | 2 |
infection model | 2 |
system simulating | 2 |
past days | 2 |
predict mortality | 2 |
study reported | 2 |
coronavirus clinical | 2 |
wenzhou medical | 2 |
circulatory diseases | 2 |
negative pressure | 2 |
covid areas | 2 |
cells via | 2 |
study shows | 2 |
test performance | 2 |
including interleukin | 2 |
higher velocity | 2 |
capillary membrane | 2 |
since february | 2 |
specifically involved | 2 |
mediated viral | 2 |
intermediate care | 2 |
serious cause | 2 |
fda ce | 2 |
natural history | 2 |
reported evidence | 2 |
septic shock | 2 |
muscarinic antagonists | 2 |
possibly due | 2 |
lymphocyte count | 2 |
alveolar macrophages | 2 |
adults hospitalized | 2 |
four cases | 2 |
severe hemoptysis | 2 |
lung fibroblasts | 2 |
respiratory rates | 2 |
coronary artery | 2 |
health workers | 2 |
random association | 2 |
high resolution | 2 |
host cells | 2 |
recently recommended | 2 |
also inhibit | 2 |
health emergency | 2 |
active patient | 2 |
novel model | 2 |
identified agent | 2 |
might help | 2 |
first hospital | 2 |
simulated pleural | 2 |
models demonstrated | 2 |
igmbecame igg | 2 |
autopsy material | 2 |
james chalmers | 2 |
model parameters | 2 |
respiratory intermediate | 2 |
pollution studies | 2 |
across many | 2 |
study may | 2 |
pneumococcal adherence | 2 |
deaths associated | 2 |
past experiences | 2 |
study quality | 2 |
pulmonary thrombotic | 2 |
lung tissues | 2 |
severe sars | 2 |
vascular abnormalities | 2 |
significant benefit | 2 |
avian influenza | 2 |
ethical issues | 2 |
cylindrical box | 2 |
systemic therapy | 2 |
curve analyses | 2 |
major concerns | 2 |
german animal | 2 |
trial version | 2 |
blood count | 2 |
official ers | 2 |
mg every | 2 |
patient care | 2 |
existing models | 2 |
radiologic findings | 2 |
related ards | 2 |
precision medicine | 2 |
another coronavirus | 2 |
study provided | 2 |
international spread | 2 |
five chinese | 2 |
epithelial integrity | 2 |
human dpp | 2 |
capillary blood | 2 |
binding site | 2 |
daily new | 2 |
nitrogen dioxide | 2 |
triage tool | 2 |
negative serology | 2 |
soluble ace | 2 |
via clinical | 2 |
china date | 2 |
studies focused | 2 |
moderate patients | 2 |
cytokines implicated | 2 |
pressure blower | 2 |
icu admissions | 2 |
consistently greater | 2 |
modified early | 2 |
pharyngeal congestion | 2 |
existing work | 2 |
unit patients | 2 |
european society | 2 |
failure rate | 2 |
low molecular | 2 |
continued access | 2 |
usually treated | 2 |
exert dual | 2 |
early due | 2 |
therapeutic strategies | 2 |
pandemic caused | 2 |
ill icu | 2 |
data sources | 2 |
renal disease | 2 |
boruta algorithm | 2 |
wear masks | 2 |
delayed viral | 2 |
poor outcome | 2 |
respiratory infectious | 2 |
respiratory specimen | 2 |
abnormal chest | 2 |
case reports | 2 |
hydroxychloroquine chloroquine | 2 |
china novel | 2 |
among different | 2 |
frequently co | 2 |
velocity model | 2 |
incremental value | 2 |
similar model | 2 |
imaging statement | 2 |
fully equipped | 2 |
cov viral | 2 |
proposed prognostic | 2 |
co contribute | 2 |
host susceptibility | 2 |
limited information | 2 |
modelling study | 2 |
using careful | 2 |
vx lzi | 2 |
progressive increase | 2 |
protein level | 2 |
year age | 2 |
prediction value | 2 |
host risk | 2 |
size airway | 2 |
tb services | 2 |
clinical evidence | 2 |
contacts occurring | 2 |
sectional study | 2 |
interpret without | 2 |
testing policies | 2 |
underwent chest | 2 |
model suggesting | 2 |
ventilator mortality | 2 |
severe events | 2 |
early discontinuation | 2 |
human immunodeficiency | 2 |
emergency room | 2 |
collected using | 2 |
ten times | 2 |
maintaining low | 2 |
based models | 2 |
ecological studies | 2 |
thrombotic microangiopathy | 2 |
medicine score | 2 |
sars patients | 2 |
models may | 2 |
interpreted cautiously | 2 |
viral spread | 2 |
liver dysfunction | 2 |
days following | 2 |
surgical masks | 2 |
support services | 2 |
uncontrolled trials | 2 |
monitoring units | 2 |
monocentric cohort | 2 |
ct chest | 2 |
review process | 2 |
viral effects | 2 |
purported advantage | 2 |
nosocomial infection | 2 |
mobile hospital | 2 |
discovery results | 2 |
immunodeficiency virus | 2 |
prospective studies | 2 |
viral replication | 2 |
days old | 2 |
vannes hospital | 2 |
molecular mechanisms | 2 |
emergency medicine | 2 |
study development | 2 |
larger dispersion | 2 |
will undoubtedly | 2 |
laboratory measurements | 2 |
death ten | 2 |
ventilated covid | 2 |
air dispersion | 2 |
molecular diagnosis | 2 |
cisplatin pemetrexed | 2 |
shelf materials | 2 |
july edition | 2 |
device companies | 2 |
rapid emergency | 2 |
confirmed patients | 2 |
rapid increase | 2 |
hazard regression | 2 |
scientific literature | 2 |
specific individual | 2 |
probable bat | 2 |
technique appears | 2 |
escalated risks | 2 |
sample collection | 2 |
ongoing studies | 2 |
clinical impact | 2 |
imaging modalities | 2 |
latter two | 2 |
prospective data | 2 |
previously identified | 2 |
initial clinical | 2 |
among critically | 2 |
decision making | 2 |
normal respiratory | 2 |
relatively contraindicated | 2 |
supplementary methods | 2 |
beyond healthy | 2 |
oral etoposide | 2 |
organization interim | 2 |
contagious affliction | 2 |
canonical tgf | 2 |
two pressure | 2 |
support devices | 2 |
retail cost | 2 |
also presented | 2 |
early studies | 2 |
medical care | 2 |
radiological patterns | 2 |
phase iii | 2 |
wuhan jinyintan | 2 |
novel therapy | 2 |
higher rate | 2 |
protective effect | 2 |
hospital resources | 2 |
haut conseil | 2 |
kg every | 2 |
synthetic sampling | 2 |
whether chemotherapy | 2 |
oxygen devices | 2 |
lung capacity | 2 |
likely negative | 2 |
pressure ventilator | 2 |
xing title | 2 |
nrs use | 2 |
pollution may | 2 |
autopsy specimens | 2 |
distress four | 2 |
st july | 2 |
beyond china | 2 |
failure requiring | 2 |
nasal cannulas | 2 |
reports clinical | 2 |
social contact | 2 |
cigarette smoke | 2 |
procedures may | 2 |
modeling studies | 2 |
spring outbreak | 2 |
help prevent | 2 |
trial design | 2 |
approval procedures | 2 |
pulmonary tuberculosis | 2 |
tb covid | 2 |
cerebrovascular diseases | 2 |
unit care | 2 |
fleischner society | 2 |
antiviral compounds | 2 |
composite measure | 2 |
potential confounding | 2 |
home spirometry | 2 |
aldosterone system | 2 |
map kinase | 2 |
plasma procalcitonin | 2 |
igg igmbecame | 2 |
rapidly evolved | 2 |
model using | 2 |
two randomised | 2 |
evaluating lung | 2 |
insidious venous | 2 |
reduce risk | 2 |
medical staff | 2 |
social measures | 2 |
low prevalence | 2 |
viral nucleic | 2 |
respiratory swabs | 2 |
including time | 2 |
common symptoms | 2 |
cardiac injury | 2 |
treatment including | 2 |
maintenance therapy | 2 |
biological availability | 2 |
significantly escalated | 2 |
trial sponsors | 2 |
accuracies ranging | 2 |
nicotinic cholinergic | 2 |
vascular enlargement | 2 |
accumulating evidence | 2 |
actively breathing | 2 |
mild respiratory | 2 |
materials available | 2 |
stronger predictor | 2 |
different strategies | 2 |
lobar perfusion | 2 |
disease units | 2 |
hospital death | 2 |
may interrupt | 2 |
matched case | 2 |
standard oxygen | 2 |
low cost | 2 |
two contributions | 2 |
changping district | 2 |
phenotyping based | 2 |
model demonstrated | 2 |
hospital employment | 2 |
larger particles | 2 |
medical research | 2 |
service delivery | 2 |
across multiple | 2 |
systematic analysis | 2 |
models among | 2 |
intended time | 2 |
chest radiograph | 2 |
pulmonary infiltrates | 2 |
laboratory tests | 2 |
pretest probability | 2 |
china impact | 2 |
molecular weight | 2 |
performed better | 2 |
advanced age | 2 |
small tumours | 2 |
noninvasive monitoring | 2 |
first one | 2 |
driven hyperinflammation | 2 |
cannula therapy | 2 |
smoking among | 2 |
health clinical | 2 |
icu ventilators | 2 |
closer monitoring | 2 |
ms group | 2 |
radiological findings | 2 |
gas may | 2 |
across regions | 2 |
broad spectrum | 2 |
interventional pulmonology | 2 |
supportive treatment | 2 |
findings show | 2 |
potential confounders | 2 |
specificities ranging | 2 |
distancing interventions | 2 |
primary prophylactic | 2 |
initially described | 2 |
typical symptoms | 2 |
abnormal findings | 2 |
data open | 2 |
lavage fluid | 2 |
contact history | 2 |
may th | 2 |
involving patients | 2 |
surgical resection | 2 |
per patient | 2 |
receiving denosumab | 2 |
blood eosinophils | 2 |
surgical mask | 2 |
thorough assessment | 2 |
large majority | 2 |
pneumonia due | 2 |
vitro data | 2 |
bdg positivity | 2 |
median disease | 2 |
large number | 2 |
extensive methods | 2 |
white cell | 2 |
multinational consensus | 2 |
angiotensin i | 2 |
delaying chemotherapy | 2 |
peer reviewe | 2 |
clinical picture | 2 |
angiotensin receptor | 2 |
algorithms may | 2 |
tuberculosis network | 2 |
traditional cigarette | 2 |
spontaneous breathing | 2 |
pulmonary artery | 2 |
cases denoted | 2 |
reduce time | 2 |
years showed | 2 |
average respiratory | 2 |
pulmonary pathology | 2 |
effective interventions | 2 |
retinoic acid | 2 |
light detection | 2 |
milk powder | 2 |
lung ct | 2 |
among consecutive | 2 |
numbers requiring | 2 |
csa affects | 2 |
mycosis study | 2 |
trial designs | 2 |
protection level | 2 |
urea nitrogen | 2 |
cardiovascular events | 2 |
dual anti | 2 |
poorly controlled | 2 |
adult covid | 2 |
hfno unit | 2 |
infection rate | 2 |
individual participant | 2 |
functional respiratory | 2 |
potential earliest | 2 |
perfusion mismatch | 2 |
newly identified | 2 |
lymphocyte proportion | 2 |
showed heavier | 2 |
dispersing differently | 2 |
recent coronavirus | 2 |
bat origin | 2 |
rapid outbreak | 2 |
fold increased | 2 |
immune cells | 2 |
mycobacterium tuberculosis | 2 |
via multiple | 2 |
ecological fallacy | 2 |
csa reduced | 2 |
none required | 2 |
emerging human | 2 |
admission date | 2 |
chest aabip | 2 |
ventilation perfusion | 2 |
comprehensive review | 2 |
one major | 2 |
final day | 2 |
liberate critical | 2 |
yb se | 2 |
additional tb | 2 |
go slow | 2 |
agent foisted | 2 |
jak inhibitor | 2 |
patient years | 2 |
belgian mycosis | 2 |
ventilator management | 2 |
findings suggested | 2 |
nano controller | 2 |
distributed variables | 2 |
patients undergoing | 2 |
goes beyond | 2 |
syndrome patients | 2 |
regional authorities | 2 |
chest medicine | 2 |
across china | 2 |
performed according | 2 |
obstructive patient | 2 |
cases tuberculosis | 2 |
may require | 2 |
pollution levels | 2 |
blood cell | 2 |
preliminary data | 2 |
upper airway | 2 |
mainly female | 2 |
people came | 2 |
progression date | 2 |
high incidence | 2 |
associated protein | 2 |
cardiogenic oedema | 2 |
radiation exposure | 2 |
restrictive diseases | 2 |
animal protection | 2 |
yuhang district | 2 |
middle income | 2 |
progression occurred | 2 |
chinese new | 2 |
data available | 2 |
clinical implications | 2 |
failure occurs | 2 |
wuhan university | 2 |
airvo tm | 2 |
immunomodulatory strategies | 2 |
become available | 2 |
isotype switching | 2 |
unpaired two | 2 |
novo oxygen | 2 |
tuberculosis transmission | 2 |
random sampling | 2 |
decreased performance | 2 |
minus net | 2 |
regulatory factor | 2 |
several issues | 2 |
showing symptoms | 2 |
novel approach | 2 |
clinical perspective | 2 |
interventions may | 2 |
washington state | 2 |
varying degrees | 2 |
interim version | 2 |
income settings | 2 |
driven approaches | 2 |
literature reports | 2 |
higher doses | 2 |
toughest triage | 2 |
designated hospitals | 2 |
several pro | 2 |
tell us | 2 |
transmembrane conductance | 2 |
might also | 2 |
guide therapy | 2 |
oxygen concentrations | 2 |
ats clinical | 2 |
viral particles | 2 |
giving cisplatin | 2 |
study towards | 2 |
may contribute | 2 |
related complications | 2 |
coronavirus infects | 2 |
mutually exclusive | 2 |
particulate matter | 2 |
longer term | 2 |
five cases | 2 |
original descriptions | 2 |
promising approach | 2 |
february th | 2 |
bigger picture | 2 |
foci formation | 2 |
commonly observed | 2 |
ct manifestations | 2 |
avoid intubation | 2 |
biologic feature | 2 |
ly kobi | 2 |
peep values | 2 |
imaging detected | 2 |
allocating ventilators | 2 |
high numbers | 2 |
feedback loop | 2 |
natural ventilation | 2 |
platinum etoposide | 2 |
asba bi | 2 |
onestep rt | 2 |
atopic dermatitis | 2 |
grow fast | 2 |
endemic human | 2 |
mathematical model | 2 |
detected vte | 2 |
larger sample | 2 |
derived using | 2 |
radiographic findings | 2 |
poor outcomes | 2 |
cigarette smoking | 2 |
increased mers | 2 |
dose dexamethasone | 2 |
poor prognosis | 2 |
past emergencies | 2 |
rate constant | 2 |
shorter dispersion | 2 |
natural features | 2 |
map kinases | 2 |
limit mycobacterium | 2 |
patients based | 2 |
confusion matrix | 2 |
diffusion test | 2 |
viral entry | 2 |
ics withdrawal | 2 |
child contact | 2 |
important feature | 2 |
generates larger | 2 |
imaging models | 2 |
new therapies | 2 |
capillary barrier | 2 |
overall survival | 2 |
protection laws | 2 |
specific treatment | 2 |
smoking increases | 2 |
antigen tests | 2 |
specific clinical | 2 |
support system | 2 |
suffer worse | 2 |
microvascular injury | 2 |
resolution ct | 2 |
written dni | 2 |
new medicines | 2 |
true prevalence | 2 |
taken together | 2 |
hubei patients | 2 |
js bk | 2 |
scans demonstrated | 2 |
similar findings | 2 |
multicenter prospective | 2 |
poor response | 2 |
controversial results | 2 |
medium size | 2 |
research questions | 2 |
sensitivities ranging | 2 |
cm width | 2 |
pneumonia may | 2 |
multicenter cohort | 2 |
covid risk | 2 |
sampling methods | 2 |
neural networks | 2 |
provide evidence | 2 |
hoc i | 2 |
asthma diagnosis | 2 |
transcription polymerase | 2 |
several ongoing | 2 |
corticosteroid treatment | 2 |
clinical progression | 2 |
breathing support | 2 |
associated invasive | 2 |
requiring mechanical | 2 |
endotracheal intubation | 2 |
class ii | 2 |
adult tobacco | 2 |
avoid maintaining | 2 |
igm became | 2 |
royal college | 2 |
spearman correlation | 2 |
reduction might | 2 |
local outbreak | 2 |
particularly high | 2 |
respiratory viral | 2 |
rate increased | 2 |
ongoing trials | 2 |
xpert mtb | 2 |
guangzhou medical | 2 |
greater severity | 2 |
higher number | 2 |
full anticoagulation | 2 |
therapies including | 2 |
greater toronto | 2 |
studies showing | 2 |
now understand | 2 |
high clinical | 2 |
thoracic fat | 2 |
presenting characteristics | 2 |
large open | 2 |
patients reported | 2 |
chemotherapy may | 2 |
using imaging | 2 |
understand thrombotic | 2 |
air trapping | 2 |
predictors using | 2 |
see online | 2 |
three scenarios | 2 |
vascular endothelialitis | 2 |
impact globally | 2 |
adequately explored | 2 |
secondary analyses | 2 |
international multicenter | 2 |
patients will | 2 |
delta net | 2 |
adverse clinical | 2 |
airway model | 2 |
requiring niv | 2 |
peking university | 2 |
include models | 2 |
demographic features | 2 |
unit stay | 2 |
pathogen discovery | 2 |
medical interventions | 2 |
febrile neutropenia | 2 |
centre data | 2 |
volunteers subjected | 2 |
recent studies | 2 |
one achieved | 2 |
scientific studies | 2 |
pneumonia outbreak | 2 |
lung involvement | 2 |
cellular viral | 2 |
trials network | 2 |
epithelial surfaces | 2 |
small fraction | 2 |
ml cmh | 2 |
diseases society | 2 |
breathing room | 2 |
overexuberant host | 2 |
air bronchogram | 2 |
purely supportive | 2 |
decline phase | 2 |
csa treated | 2 |
covid infection | 2 |
antibiotic therapy | 2 |
force groups | 2 |
new therapeutic | 2 |
automatic continuous | 2 |
pressure signal | 2 |
several studies | 2 |
breath carbon | 2 |